SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
M3 Module 5: PH10
Acute granulocytic leukemia
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute myeloid leukemia, NOS
Acute myeloid leukemia with cytoplasmic nucleophosmin (NPMc + AML)
Acute myeloid leukemia with mutated CEBPA
Acute myeloid leukemia with mutated NPM1
Acute non-lymphocytic leukemia
Chronic lymphocytic leukemia in blast crisis
Chronic lymphocytic leukemia in blast phase
Chronic lymphocytic leukemia with greater than 20% blasts in bone marrow
CLL in blast crisis
CLL in blast phase
CLL with greater than 20% blasts in bone marrow
Myeloid neoplasm, NOS (bone marrow involved only)
Cases of AML that do not fulfill the criteria for AML with recurrent genetic abnormalities, AML with multilineage dysplasia or AML and MDS, therapy-related fall into this category. The defining criterion for AML is 20% or more blasts in the blood or bone marrow.
This is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age.
Acute myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification. In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. If no information is found in the medical record, follow-back to the attending physician should be done. More specific myeloid leukemias include: Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1; Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB/MYH11; Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26;2); RPN1-EVI1; Acute myeloid leukemia with maturation; Acute myeloid leukemia with minimal differentiation; Acute myeloid leukemia with mutated CEBPA; Acute myeloid leukemia with mutated NPM1; Acute myeloid leukemia with myelodysplasia-related changes; Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214; Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1; Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL; Acute myeloid leukemia without maturation; Myeloid leukemia associated with Down syndrome; and Myeloid neoplasm with PDGFRB arrangement. When a more specific diagnosis is identified, the histology should be changed to the more specific neoplasm name and code. See the histology tables for more information on NOS and more specific histologies.
This code is also used for AML with mutated NPM1 and AML with mutated CEBPA. Note in your abstract whether this is AML, NOS or AML with mutated NPM1 or DEBPA. If the diagnosis is either of these specific AML the histology code should not be changed.